Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus
| dc.contributor.author | Pacheco-Lugo, L | |
| dc.contributor.author | Sáenz-García, J | |
| dc.contributor.author | Navarro Quiroz, E | |
| dc.contributor.author | González Torres, H | |
| dc.contributor.author | Fang, L | |
| dc.contributor.author | Díaz-Olmos, Y | |
| dc.contributor.author | Garavito de Egea, G | |
| dc.contributor.author | Egea Bermejo, E | |
| dc.contributor.author | Aroca Martínez, G | |
| dc.date.accessioned | 2018-11-22T14:33:12Z | |
| dc.date.available | 2018-11-22T14:33:12Z | |
| dc.date.issued | 2018-11 | |
| dc.description.abstract | Background: Systemic lupus erythematosus is a heterogeneous chronic inflammatory autoimmune disorder characterized by an exacerbated expression of cytokines and chemokines in different tissues and organs. Renal involvement is a significant contributor to the morbidity and mortality of systemic lupus erythematosus, and its diagnosis is based on renal biopsy, an invasive procedure with a high risk of complications. Therefore, the development of alternative, non-invasive diagnostic tests for kidney disease in patients with systemic lupus erythematosus is a priority. Aim: To evaluate the plasma levels of a panel of cytokines and chemokines using multiplex xMAP technology in a cohort of Colombian patients with active and inactive systemic lupus erythematosus, and to evaluate their potential as biomarkers of renal involvement. Results: Plasma from 40 systemic lupus erythematosus non-nephritis patients and 80 lupus nephritis patients with different levels of renal involvement were analyzed for 39 cytokines using Luminex xMAP technology. Lupus nephritis patients had significantly increased plasma eotaxin, TNF-a, interleukin-17-a, interleukin-10, and interleukin-15 as compared to the systemic lupus erythematosus non-nephritis group. Macrophage-derived chemokine, growth regulated oncogene alpha, and epidermal growth factor were significantly elevated in systemic lupus erythematosus non-nephritis patients when compared to lupus nephritis individuals. Plasma eotaxin levels allowed a discrimination between systemic lupus erythematosus non-nephritis and lupus nephritis patients, for which we performed a receiver operating characteristic curve to confirm. We observed a correlation of eotaxin levels with active nephritis (Systemic Lupus Erythematosus Disease Activity Index). Our data indicate that circulating cytokines and chemokines could be considered good predictors of renal involvement in individuals with systemic lupus erythematosus. | eng |
| dc.identifier.issn | 09612033 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12442/2356 | |
| dc.language.iso | eng | eng |
| dc.publisher | Sage Publising | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.license | Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional | eng |
| dc.source | Revista Lupus | spa |
| dc.source.uri | https://journals.sagepub.com/doi/full/10.1177/0961203318812679 | eng |
| dc.subject | Biomarkers | eng |
| dc.subject | Cytokines | eng |
| dc.subject | Eotaxin | eng |
| dc.subject | Lupus nephritis | eng |
| dc.subject | Systemic lupus erythematosus | eng |
| dc.title | Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus | eng |
| dc.type | article | eng |
| dcterms.references | Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015; 11: 329–341. | eng |
| dcterms.references | Moroni G, Quaglini S, Radice A, et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J Immunol Res 2015; 2015: 1–8. | eng |
| dcterms.references | Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol JASN 2004; 15: 241–250. | eng |
| dcterms.references | Misra R, Gupta R. Biomarkers in lupus nephritis. Int J Rheum Dis 2015; 18: 219–232. | eng |
| dcterms.references | Mok CC. Biomarkers for lupus nephritis: A critical appraisal. J Biomed Biotechnol 2010; 2010: 1–11. | eng |
| dcterms.references | Liang MH, Schur PH, Fortin P, et al. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421–432. | eng |
| dcterms.references | Chen T, Estrella M, Fine D. Predictors of kidney biopsy complication among patients with systemic lupus erythematosus. Lupus 2012; 21: 848–854. | eng |
| dcterms.references | Azoica˘ i T, Belibou IM, Lozneanu L, et al. Large variability of the activity and chronicity indexes within and between histological classes of lupus nephritis. Rom JMorphol Embryol 2017; 58: 73–78. | eng |
| dcterms.references | Dossus L, Becker S, Achaintre D, et al. Validity of multiplex-based assays for cytokine measurements in serum and plasma from ‘nondiseased’ subjects: Comparison with ELISA. J Immunol Methods 2009; 350: 125–132. | eng |
| dcterms.references | Elshal M, Mccoy J. Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA? Methods 2006; 38: 317–323. | eng |
| dcterms.references | Leng SX, McElhaney JE, Walston JD, et al. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 2008; 63: 879–884. | eng |
| dcterms.references | Gladman DD, Iban˜ ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291. | eng |
| dcterms.references | Yap DYH, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010; 2010: 1–10. | eng |
| dcterms.references | Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus? Focus on targeting interferonalpha. Clin Immunol 2012; 143: 210–221. | eng |
| dcterms.references | Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011; 40: 138–150. | eng |
| dcterms.references | Watson L, Beresford MW. Urine biomarkers in juvenile-onset SLE nephritis. Pediatr Nephrol 2013; 28: 363–374. | eng |
| dcterms.references | Lu J, Kwan BC-H, Lai FM-M, et al. Gene expression of TWEAK/ Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis: Intra-renal gene expression in SLE. Nephrology 2011; 16: 426–432. | eng |
| dcterms.references | Blanco P. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540–1543. | eng |
| dcterms.references | Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Iglike lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 1136–1145. | eng |
| dcterms.references | Cheng Q, Mumtaz IM, Khodadadi L, et al. Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis 2013; 72: 2011–2017. | eng |
| dcterms.references | Navarro-Quiroz E, Pacheco-Lugo L, Lorenzi H, et al. Highthroughput sequencing reveals circulating miRNAs as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. PLOS ONE 2016; 11: e0166202. | eng |
| dcterms.references | Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: A (co-)evolutionary perspective. Nat Rev Immunol 2009; 9: 883–889. | eng |
| dcterms.references | Elewa EA, Zakaria O, Mohamed EI, et al. The role of interleukins 4, 17 and interferon gamma as biomarkers in patients with systemic lupus erythematosus and their correlation with disease activity. Egypt Rheumatol 2014; 36: 21–27. | eng |
| dcterms.references | Wong CK, Ho CY, Li EK, et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589–593. | eng |
| dcterms.references | Zhao X-F, Pan H-F, Yuan H, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37: 81–85. | eng |
| dcterms.references | Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL- 17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine 2015; 76: 280–287. | eng |
| dcterms.references | Postal M, Appenzeller S. The role of tumor necrosis factor-alpha (TNF-a) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011; 56: 537–543. | eng |
| dcterms.references | Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303–308. | eng |
| dcterms.references | Sabry A, Sheashaa H, Elhusseini A, et al. Proinflammatory cytokines (TNF-a and IL-6) in Egyptian patients with SLE: Its correlation with disease activity. Cytokine 2006; 35: 148–153. | eng |
| dcterms.references | Studnicka-Benke A, Steiner G, Petera P, et al. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067–1074. | eng |
| dcterms.references | Go´ mez D, Correa PA, Go´ mez LM, et al. Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor alpha protective? Semin Arthritis Rheum 2004; 33: 404–413. | eng |
| dcterms.references | Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5–8. | eng |
| dcterms.references | Preble OT, Black RJ, Friedman RM, et al. Systemic lupus erythematosus: Presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429–431. | eng |
| dcterms.references | Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207–210. | eng |
| dcterms.references | Kitaura M, Suzuki N, Imai T, et al. Molecular cloning of a novel human cc chemokine (eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999; 274: 27975–27980. | eng |
| dcterms.references | Paplińska M, Hermanowicz-Salamon J, Nejman-Gryz P, et al. Expression of eotaxins in the material from nasal brushing in asthma, allergic rhinitis and COPD patients. Cytokine 2012; 60: 393–399. | eng |
| dcterms.references | Owczarek W, Paplińska M, Targowski T, et al. Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis. Cytokine 2010; 50: 181–185. | eng |
| dcterms.references | Wu D, Zhou J, Bi H, et al. CCL11 as a potential diagnostic marker for asthma? J Asthma 2014; 51: 847–854. | eng |
| dcterms.references | Adar T, Shteingart S, Ben Ya’acov A, et al. From airway inflammation to inflammatory bowel disease: Eotaxin-1, a key regulator of intestinal inflammation. Clin Immunol 2014; 153: 199–208. | eng |
| dcterms.references | Kokkonen H, So¨ derstro¨m I, Rocklo¨ v J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010; 62(2): 383–391. | eng |
| dcterms.references | Chae S-C, Park Y-R, Shim S-C, et al. Eotaxin-3 gene polymorphisms are associated with rheumatoid arthritis in a Korean population. Hum Immunol 2005; 66: 314–320. | eng |
| dcterms.references | Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016; 165: 1548–1550. | eng |
| dcterms.references | Menzies-Gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002; 169: 2712–2718. | eng |
| dcterms.references | Huaux F, Gharaee-Kermani M, Liu T, et al. Role of eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycininduced lung injury and fibrosis. Am J Pathol 2005; 167: 1485–1496. | eng |
| dcterms.references | Huber AK, Wang L, Han P, et al. Dysregulation of the IL-23/IL- 17 axis and myeloid factors in secondary progressive MS. Neurology 2014; 83: 1500–1507. | eng |
| dcterms.references | Liao X, Pirapakaran T, Luo XM. Chemokines and chemokine receptors in the development of lupus nephritis. Mediators Inflamm 2016; 2016: 1–15. | eng |
| dcterms.references | Rollins BJ. Chemokines. Blood 1997; 90: 909–928. | eng |
| dcterms.references | Ransohoff RM. Chemokines and chemokine receptors: Standing at the crossroads of immunobiology and neurobiology. Immunity 2009; 31: 711–721. | eng |
| dcterms.references | Hanaoka H, Okazaki Y, Hashiguchi A, et al. Overexpression of CXCR4 on circulating B cells in patients with active systemic lupus erythematosus. Clin Exp Rheumatol 2015; 33: 863–870. | eng |
| dcterms.references | Worthmann K, Gueler F, von Vietinghoff S, et al. Pathogenetic role of glomerular CXCL13 expression in lupus nephritis: Glomerular CXCL13 expression in SLE. Clin Exp Immunol 2014; 178: 20–27. | eng |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- PlasmaCytokinesPotentialBiomarkersKidneyDamagePatientsSystemicLupus.pdf
- Tamaño:
- 804.38 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 368 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: